Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

54
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
54
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

39
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1...
39
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

8
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
8
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

9
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
9
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

11
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
11
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atrophy of the optic chiasm is associated with microvascular diabetic complications in type 1 diabetes.

Frontiers in endocrinology·2023
Same author

Genome-wide mRNA profiling in urinary extracellular vesicles reveals stress gene signature for diabetic kidney disease.

iScience·2023
Same author

The impact of diabetic nephropathy and severe diabetic retinopathy on chronic limb threatening ischemia risk in individuals with type 1 diabetes: a nationwide, population study.

The Lancet regional health. Europe·2023
Same author

Reduced methylation correlates with diabetic nephropathy risk in type 1 diabetes.

The Journal of clinical investigation·2023
Same author

Epigenome-wide meta-analysis identifies DNA methylation biomarkers associated with diabetic kidney disease.

Nature communications·2022
Same author

Whole-exome sequencing identifies novel protein-altering variants associated with serum apolipoprotein and lipid concentrations.

Genome medicine·2022

Related Experiment Video

Updated: Apr 24, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.6K

Predicting major outcomes in type 1 diabetes: a model development and validation study.

Sabita S Soedamah-Muthu1, Yvonne Vergouwe, Tina Costacou

  • 1Division of Human Nutrition, Wageningen University, Bomenweg 2, PO Box 8129, 6700 EV, Wageningen, the Netherlands, sabita.soedamah-muthu@wur.nl.

Diabetologia
|September 5, 2014
PubMed
Summary
This summary is machine-generated.

A new prognostic model using clinical factors accurately predicts major vascular complications and death in type 1 diabetes patients. This tool aids early risk classification for better patient management and clinical trial stratification.

More Related Videos

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

8.0K
Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas
03:07

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas

Published on: November 11, 2025

567

Related Experiment Videos

Last Updated: Apr 24, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.6K
A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

8.0K
Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas
03:07

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas

Published on: November 11, 2025

567

Area of Science:

  • Endocrinology
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Type 1 diabetes (T1D) significantly increases the risk of major vascular complications and mortality.
  • Early identification of high-risk T1D patients is crucial for effective management and intervention.
  • Existing risk prediction methods may lack accuracy or accessibility for routine clinical use.

Purpose of the Study:

  • To develop and validate a prognostic model for predicting major adverse outcomes in individuals with T1D.
  • To assess the model's performance in independent, diverse patient cohorts.
  • To provide a tool for improved risk stratification in T1D clinical practice and research.

Main Methods:

  • A Weibull regression model was developed using data from 1,973 T1D participants in the EURODIAB study.
  • Key prognostic factors identified included age, HbA1c, waist-to-hip ratio (WHR), albumin/creatinine ratio, and HDL-cholesterol.
  • Model performance was validated in three independent cohorts: EDC (n=554), FinnDiane (n=2,999), and CACTI (n=580).

Main Results:

  • The model identified age, HbA1c, WHR, albumin/creatinine ratio, and HDL-cholesterol as significant prognostic factors.
  • The model demonstrated adequate discriminative ability in the EURODIAB cohort with a C-statistic of 0.74.
  • Validation cohorts showed similar or superior discrimination: EDC (0.79), FinnDiane (0.82), and CACTI (0.73).

Conclusions:

  • A prognostic model utilizing readily available clinical features effectively differentiates T1D patients with good versus poor prognosis.
  • This model shows promise for enhancing clinical practice and risk stratification in T1D research and trials.
  • The validated model offers a practical tool for identifying T1D patients who require closer monitoring and intervention.